Figure 7 | Scientific Reports

Figure 7

From: Synergy of ruthenium metallo-intercalator, [Ru(dppz)2(PIP)]2+, with PARP inhibitor Olaparib in non-small cell lung cancer cells

Figure 7

Morphological changes of the zebrafish embryos upon Ru-PIP or Olaparib treatment. (a) Morphological assessment of zebrafish embryonic development. (A–C) Normal zebrafish embryonic development at 96 hpf; (D–G) dead or coagulated embryos; (H–I) Non hatching; (J–P) morphological abnormalities; pericardial edema (PE), yolk sac edema (YSE), and spinal deformity (SD). (b) Morphological abnormalities of zebrafish embryos upon treatments with Ru-PIP, Olaparib, Ru-PIP/Olaparib combination and cisplatin at 96 hpf. Subtoxic concentration of Olaparib was used in the combination treatment (5 mg/L). Data expressed as percentage of morphological abnormalities observed of twenty-four embryos from two independent experiments. **P < 0.01, ***P < 0.001 compared to control group by ANOVA.

Back to article page